Background: The development of new microvessels in the surrounding stroma is a prerequisite for tumour progression. Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are angiogenic factors expressed in a broad range of human tumours. We have measured the concentrations of both cytokines in the serum of patients with advanced colorectal cancer. We questioned whether these levels are related to the number of tumour sites, the volume of liver and/or lung involvement and the growth kinetics.
Introduction
In recent cancer research the interest is shifting towards the stroma] eel] compartment which is associated with the neoplastic cell compartment. Endothelial cells are present in the tumour stroma with a ratio of 1:10 to 1:100 as compared to the number of tumour cells [1] . Angiogenesis relies on endothelial cell migration, proliferation and differentiation. This process of new vessel development, partly reflecting the characteristics of the genetically unmodified stromal tissue of the host, is involved in the three key pathophysiologjcal events in the disease progression in cancer tumour cell proliferation, invasion and hematogenous spread, i) Tumour cell proliferation is positively influenced by the development of new microvessels in the stroma by a combination of the perfusion effect and the reciprocal paracrine interaction between tumour and endothelial cells [1] . ii) Local tumour cell invasion is facilitated by extracellular matrix breakdown by endothelial cells migrating from the wall of preexisting vessels [2] . iii) Finally, hematogenous spread of tumour cells is quantitatively related to intratumoural microvessel density (IMD), as shown both by animal experiments [3] and preliminary clinical studies [4] .
The activation of the endothelial cells during angiogenesis is governed by the net result of the locoregional imbalance between angiogenic peptides and inhibitors [5] . bFGF and VEGF are two heparin-binding factors with potent angiogenic properties both in vivo and in vitro. [6, 7] They act synergistically in in vitro angiogenesis models [8] . VEGF is the only known endothelial cell specific angiogenic factor [7] . bFGF, next to its paracrine effect, is involved in an autocrine loop stimulating endothelial cell proliferation [6] .
Both bFGF and VEGF can be detected in human body fluids with specific enzyme-linked immunosorbent assays (ELISA) [9, 10] . Urinary or serum concentrations of bFGF and VEGF were found to be elevated in a variable proportion of different types of cancer patients [11, 12] . The presence of bFGF in the cerebrospinal fluid of children with a brain tumour was shown to be predictive for early tumour recurrence and to be positively correlated with IMD [13] . Intratumoural VEGF levels measured by ELISA in primary breast cancer were found to be significantly higher in vas-cularly rich tumours than in vascularly poor tumours [14] .
We report the quantification of serum bFGF and VEGF concentrations using ELISA in 44 patients with untreated metastatic and/or locally advanced colorectal adenocarcinoma. We questioned whether the concentrations are associated with the number of metastatic sites, the extent of target organ involvement and with the kinetic profile of the metastases.
Patients and methods
From January 1995 on, 46 patients who had developed distant metastasis and/or local relapse of a primary colorectal adenocarcinoma were entered into the study. Of all of the patients radiologic documents were available, taken at least with a 3-month interval, during which no antitumour measures have been initiated. Two patients were lost to follow-up. Of the 44 patients, 3 still had their primary tumour. None of the patients received any form of chemotherapy, radiotherapy or surgery during the observation period. Most of the patients had been given 5-fluorouracil based chemotherapy prior to this observation period and had progressed. Liver metastasis were present in 31 patients, lung metastasis in 12, skin in 3, bone in 2, peritoneal metastasis in 3 and lymph node involvement in 3. Local relapse was present in 14 patients. Successive serum levels of bFGF and VEGF were determined during the follow-up period (mean duration of 9.3 months; median of 9.5 months) using two ELISA-kits of R&D Systems Inc., Minneapolis, MN (Quantikine High Sensitivity human FGF basic and Quantikine human VEGF). A total of 105 samples were analysed per factor. A mean of 2.4 serum samples were investigated per patient (median: 2.0). Elevated bFGF and VEGF levels were defined as to be greater than the 95th percentile value in the normal control subject group described by R&D Systems Inc. This resulted in a cut-off value for bFGF of 7.5 pg/ml and for VEGF of 500 pg/ml. In 88% of the patients the bFGF and VEGF level regarded as a categorical variable, being either elevated or not, was stable throughout the followup period. The value of the first measurement done during the follow-up period was therefore taken for further analysis.
Patients were grouped according to the number of metastatic sites (one or multiple), according to the semi quantitative assessment on radiologic imaging studies of the extent of organ involvement for both liver and lung (>25% or <25%) and according to the tumour growth kinetics, determined on successive computer tomographic (CT) images. Tumour doubling time was defined as the interval after which the product of the largest perpendicular diameters of a metastatic lesion had at least doubled. In patients with multiple lesions the growth kinetics were based on the most rapidly progressing lesion.
For 5 patients successive CT scans were available only for a shorter untreated period than six months (3, 4, 4, 4, and 5 months, respectively). Calculations of tumour doubling time were then made based on the assumption of a linear growth curve. In two patients, a biphasic pattern of growth kinetics of the metastases was observed. The first serum determination of each growth phase was taken for further analysis.
A total of 46 data sets (VEGF and bFGF level) were obtained in this way, related to 44 patients. For growth kinetics, the data sets were divided into two groups: volume doubling time of a representative metastatic lesion of less than 6 months versus more than 6 months. Each group contained 23 data sets.
Statistical analysis Results

Serum bFGF and VEGF levels as continuous variables: Association with growth kinetics
A mean bFGF serum level of 7.918.9 (Standard Deviation (SD)) (median: 4.6) pg/ml was found for the 44 patients. For VEGF the mean was 462 ± 338 (SD) pg/ml (median: 351). There was a significant difference for both the VEGF and the bFGF levels when patients characterised by a fast progression of the metastases (n -23) were compared to the patients showing a slow metastatic growth (Table 1, Figures 1 and 2 ). There was no correlation between VEGF and bFGF serum levels (simple linear regression: r = 0.3, P m 0.04).
Serum bFGF and VEGF levels as categorical variables: Association with growth kinetics
When 7.5 pg/ml was taken as a cut-off for bFGF and 500 pg/ml as a cut-off for VEGF, a significant differ- Serum levels (pg/ml) metastatic sites (Table 3) , nor with the extent/pattern of organ involvement (Table 4) . VEGF levels were higher in patients with local relapse or with a primary tumour present. ence in the distribution of patients in the two tumour growth kinetics groups was observed ( Table 2 ). Only one patient of the fast progressing group (n-23) had a normal bFGF and a normal VEGF serum level. No patient in the slowly progressing group (n = 23) had an elevated bFGF and only two showed an elevated VEGF. Accordance for bFGF and VEGF serum levels as categorical variables was reached in 65% of all 46 data sets, in 43% of the fast progressing data sets and in 83% of the slowly progressing data sets.
Serum bFGF and VEGF levels as continuous variables: Association with the number and the extent/pattern of organ involvement of the metastases
Subsets of patients were created according to the number of metastatic sites: one versus multiple sites. Both groups contained 23 data sets. Three groups were defined according the metastatic extent/pattern: i) less than 25% of liver and/or lung occupied by metastases onCT(n= 12), ii) more than 25% (n -12), and iii) distant metastasis in combination with local relapse or in combination with the presence of the primary tumour (n = 18). In general there was no association of the level of serum bFGF or VEGF with the number of Metastatic pattern: 1 -lung < 25%, liver <25%, lung and liver both < 25%; 2 -lung > 25%, liver > 25%, combination of lung or liver with other metastatic sites; 3 -local relapse with or without other metastatic sites or primary tumour present in combination with other metastatic sites. Four datasets did not fit into one of the categories. Two-way table of the number of patients characterized by the volume doubling time (Tvolx2) of the representative metastases (cut-off of 6 months) and by the bFGF (cut-off 7.5 pg/ml) serum levels and the VEGF (cut-off 500 pg/ml) serum levels: number (percentage of the total in each Tvolx2 group) -Chi-squared test Discussion Expansion and spread via the bloodstream of a tumour cell population must be preceded by the development of capillaries in the host tissue [15] . Local invasion of tumour cells is facilitated by angiogenesis [2] . We have demonstrated a nearly two-fold increase in IMD in areas of invasive colorectal adenocarcinoma as compared to IMD in areas of in situ growth [16] . In this study, we have determined bFGF and VEGF levels in the serum of metastatic colorectal cancer patients using ELISA. Early reports have detected elevated urine and serum levels of bFGF in part of the patients with a broad spectrum of tumour types [11, 17] . In the sera of both cancer patients and tumour-bearing animals elevated levels of VEGF have been reported [10, 18] .
Several observations led us to investigate the association of tumour growth kinetics with the serum levels of both angiokines. i) About 45% of the patients in our study had a combined normal bFGF and normal VEGF serum level. Urine bFGF levels in a wide variety of patients with metastatic solid cancer were also found to be within a normal range in up to half of the patients [11] . ii) There was no association of the amount of circulating bFGF or VEGF with the tumour volume or with the metastatic pattern of organ involvement. From the observations i) and ii) it can be argued that the presence of tumour is not invariably associated with elevated bFGF or VEGF serum concentrations, iii) Preliminary results of preoperative serum levels in curable colorectal cancer patients are also not invariably high, but the removal of the primary tumour clearly decreased serum levels of both cytokines to within normal limits in most of the patients (data not shown). This clearly demonstrates that increased concentrations of both VEGF and bFGF are due to the presence of rumour, iv) Several studies have suggested a role for bFGF and VEGF in the process of tumour angiogenesis in colorectal carcinoma [19] [20] [21] [22] . v) We have found an association between the fraction of cycling tumour cells, measured in the maximally Ki-67 immunostained areas, and vascularity, measured in the vascular hot spots, in colorectal cancer [29] . Takahashi et al. have also noticed a direct correlation of IMD and the fraction of proliferating cell nuclear antigen (PCNA) positive tumour cells in colorectal cancer [19] .
Independently of tumour volume, a strong association was found between the growth kinetics of the metastases and the bFGF or VEGF serum levels. When the results of both angiokines were combined, this became even more significant. Almost all patients with a small volume doubling time of the metastases (less than 6 months) had bFGF and/or VEGF serum concentrations above the cut-off value. Only about 10% of the patients with slow disease progression (volume doubling time of more than 6 months) expressed elevated serum angiokine levels ( Table 2 ). Taken together, this suggests that active tumour growth and the associated new vessel development might be responsible for an increased production and release into the circulation of bFGF and VEGF. Tumour volume assessed on CT images, apart from lacking information on the amount of viable tumour tissue, does not predict the serum bFGF or VEGF status of advanced colorectal cancer patients.
An association between circulating levels of angiogenic factors and the kinetics of tumour volume increase has not been reported before. The results of studies concerning the expression of bFGF and VEGF in different tumour types [11, 12, 23] and separately in breast [14, [24] [25] [26] and gastrointestinal cancer [19, 27] are summarised in Table 5 . In half of the studies a relation between overexpression of bFGF or VEGF and survival has been reported.
We have preliminary data in other tumour types confirming the results in colorectal cancer [28] . In lowgrade sarcomas (data not shown, n -6) bFGF and VEGF serum levels were found to be invariably low (mean 0.9 pg/ml; SD 0.6; median 1,1 and mean 199 pg/ml; SD 56; median 171, respectively) as compared to the elevated levels observed in all of 4 high-grade sarcomas (mean 19.9 pg/ml; SD 8.9, median 16.5 and 401 pg/ml; SD 278; median 394). The same pattern was encountered in lymphomas. Patients with highgrade lymphomas (n -3) had a mean VEGF of 1159 pg/ml in the serum (SD 131; median 1205) and a mean bFGF of 7.2 pg/ml (SD 6.8; median 4.5) as compared to patients with low-grade lymphoma (n = 3) having a mean VEGF of 230 pg/ml (SD 92; median 280) and a mean bFGF of 1.5 pg/ml (SD 1.5; median 1.1). In both these tumour types, grade reliably predicts the clinical course, with the high-grade malignancies being characterised by a fast progression. The highest levels were measured in the serum of patients with metastatic teratocarcinoma. These preliminary results corroborate the association of tumour progression and elevated serum bFGF and VEGF levels in metastatic colorectal cancer.
As recently reported in colorectal cancer [19] and in breast cancer [14] , there was no association between the level of bFGF and the level of VEGF in the serum of our patients. This might indicate that tumour growth is associated with different angiogenic pathways in colorectal cancer. Given the synergistic effect of bFGF and VEGF on in vitro angiogenesis, it might be worthwhile to analyse on a larger population whether coexpression of these factors is related to more rapid tumour progression.
On the basis of our findings, a prospective analysis of the predictive value of bFGF and VEGF serum levels for the clinical course in metastatic colorectal cancer needs to be initiated. The time course of the serum levels might allow for the diagnosis of preclinical metastasis. Also, the role of serum determination of angiokine levels in the process of therapy monitoring warrants further investigation. Progression markers are much needed in daily clinical oncology in order to initiate palliative chemotherapy in patients likely to benefit most; i.e., those with rapidly progressive dis- Table 5 . Overview of studies analysing bFGF and VEGF expression in human tumours (mixed histology, breast cancer, gastrointestinal cancer).
Tumour type
Various [11] Various [23] Various [12] Breast cancer [24] Breast cancer [25] Breast cancer [14] Breast cancer [26] Colorectal cancer [19] Gastric cancer [27] OS -overall survival; RFS -relapse free survival; microvessel density; PCNA -proliferating cell nuclear ease. In the light of the ongoing anti-angiogenic therapeutical trials, treatment might also be tailored on the basis of the angiogenic profile of a particular patient.
